

**THE LANCET PUBLISHES RESULTS FROM PIVOTAL STUDY OF EISAI'S
HALAVEN® IN PATIENTS WITH LATE-STAGE METASTATIC BREAST CANCER**

Phase III Study Demonstrated that HALAVEN® Met its Primary Endpoint of Overall Survival

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that results from a pivotal study with HALAVEN® (eribulin mesylate), a novel anticancer agent discovered and developed by

